Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multidrug-resistant tuberculosis.
Chiang CY, Van Deun A, Trébucq A, Piubello A, Schwoebel V, Rieder HL. Chiang CY, et al. Among authors: schwoebel v. Lancet. 2019 Jul 27;394(10195):299. doi: 10.1016/S0140-6736(19)30046-7. Lancet. 2019. PMID: 31354138 No abstract available.
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
Van Deun A, Decroo T, Tahseen S, Trébucq A, Schwoebel V, Ortuno-Gutierrez N, de Jong BC, Rieder HL, Piubello A, Chiang CY. Van Deun A, et al. Among authors: schwoebel v. Int J Antimicrob Agents. 2020 Jan;55(1):105822. doi: 10.1016/j.ijantimicag.2019.10.003. Epub 2019 Oct 15. Int J Antimicrob Agents. 2020. PMID: 31626907
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.
Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, Brode S, Campbell JR, Casas EC, Conradie F, Dravniece G, du Cros P, Falzon D, Jaramillo E, Kuaban C, Lan Z, Lange C, Li PZ, Makhmudova M, Maug AKJ, Menzies D, Migliori GB, Miller A, Myrzaliev B, Ndjeka N, Noeske J, Parpieva N, Piubello A, Schwoebel V, Sikhondze W, Singla R, Souleymane MB, Trébucq A, Van Deun A, Viney K, Weyer K, Zhang BJ, Ahmad Khan F. Abidi S, et al. Among authors: schwoebel v. Eur Respir J. 2020 Mar 20;55(3):1901467. doi: 10.1183/13993003.01467-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 31862767 Free article.
The looming threat of bedaquiline resistance in tuberculosis.
Chiang CY, Trébucq A, Piubello A, Rieder HL, Schwoebel V, Van Deun A. Chiang CY, et al. Among authors: schwoebel v. Eur Respir J. 2020 Jun 4;55(6):2000718. doi: 10.1183/13993003.00718-2020. Print 2020 Jun. Eur Respir J. 2020. PMID: 32499309 Free article. No abstract available.
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.
Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, Hassane S, Souleymane B, Piubello A, Ciza F, Fikouma V, Gasana M, Ouedraogo M, Gninafon M, Van Deun A, Cirillo DM, Koura KG, Rieder HL. Trébucq A, et al. Among authors: schwoebel v. Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25. doi: 10.5588/ijtld.17.0498. Epub 2017 Nov 17. Int J Tuberc Lung Dis. 2018. PMID: 29149917
Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.
Ngabonziza JCS, Diallo AB, Tagliani E, Diarra B, Kadanga AE, Togo ACG, Thiam A, de Rijk WB, Alagna R, Houeto S, Ba F, Dagnra AY, Ivan E, Affolabi D, Schwoebel V, Trebucq A, de Jong BC, Rigouts L, Daneau G; “Union short MDR-TB regimen study group”. Ngabonziza JCS, et al. Among authors: schwoebel v. PLoS One. 2017 Oct 31;12(10):e0187211. doi: 10.1371/journal.pone.0187211. eCollection 2017. PLoS One. 2017. PMID: 29088294 Free PMC article.
Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries.
Schwœbel V, Trébucq A, Kashongwe Z, Bakayoko AS, Kuaban C, Noeske J, Harouna SH, Souleymane MB, Piubello A, Ciza F, Fikouma V, Gasana M, Ouedraogo M, Gninafon M, Van Deun A, Tagliani E, Cirillo DM, Koura KG, Rieder HL. Schwœbel V, et al. EClinicalMedicine. 2020 Feb 10;20:100268. doi: 10.1016/j.eclinm.2020.100268. eCollection 2020 Mar. EClinicalMedicine. 2020. PMID: 32300732 Free PMC article.
High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
Souleymane MB, Piubello A, Lawan IM, Hassane-Harouna S, Assao-Neino MM, Soumana A, Hamidou-Harouna Z, Gagara-Issoufou A, Ortuño-Gutiérrez N, Roggi A, Schwoebel V, Mamadou S, Lynen L, De Jong B, Van Deun A, Decroo T. Souleymane MB, et al. Among authors: schwoebel v. Eur Respir J. 2021 Jan 21;57(1):2002250. doi: 10.1183/13993003.02250-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 32703777 Free article.
62 results